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Aims
Patients’ advocates, regulators and doctors have the con-
stant objective to make the best treatments quickly avail-
able to patients. Compassionate use programmes (CUP) as
defined by the EU Regulation (EC) № 726/2004 article
83.2 are designed to provide early access before the mar-
keting authorisation (MA) of a medicine. It is necessary to
evaluate the achievements of the present legislations on
CUP in Europe in order to propose actions that could
integrate CUP into an improved orphan drug development
model.
Rationale
The European legislation is not applied on the same way
in the Member States (MS) even if in almost all MS a
scheme for CUP exists. The experience of the European
Medicines Agency, MS and companies is that this lack of
harmonisation makes difficult the early access to impor-
tant new medicines particularly for rare diseases.
Methods
Series of workshops with all stakeholders and a survey
conducted by EURORDIS in 2010-2011 via a question-
naire to 64 holders of a marketing authorisation for an
orphan medicinal product helped analysing current prac-
tices across Europe, experience at the European Medicines
Agency’s (EMA) level, and how CUPs are inserted in the
general development of an orphan medicinal product.
Results
The survey showed the obstacles in the implementation of
such programmes, and also their benefits. By enlarging the
number of patients exposed to a new product, CUPs can
expand the number of exposed patients in safety databases
by 320%. Nine products with a CUP were reviewed, some
programmes starting early in the development of the pro-
duct, others lately. Only France could provide all 9 pro-
ducts on a compassionate basis, while 3 countries could
provide a programme for 5-6 products, 5 countries for 3-4
products, 23 countries to 1-2 products, and 10 did not
provide any product on a compassionate basis.
The French Temporary Use Authorisation system
(A.T.U) illustrates the benefit for public health CUPs
can represent: combining early access to drugs for
patients, close control by the competent authority of the
use of new drugs and appropriate information of stake-
holders. France could provide 72% of the 64 authorised
orphan medicinal products on a compassionate basis in
average 35 months prior to the MA.
Main conclusions
This work led to an initiative to improve information and
transparency about CUPs in Europe, and also to propose
good practices in this domain. In order to improve the
situation it is proposed to pursue the dialogue with MS
and companies and to set up a “Facilitation group”
between MS in order to exchange information and to
build up on common experiences.
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